Compare BRSP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRSP | CMPS |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.9M | 778.7M |
| IPO Year | 2017 | 2020 |
| Metric | BRSP | CMPS |
|---|---|---|
| Price | $5.58 | $5.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.33 | ★ $27.14 |
| AVG Volume (30 Days) | 904.6K | ★ 2.5M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.70% | N/A |
| EPS Growth | ★ 75.24 | 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,587,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $2.25 |
| 52 Week High | $6.17 | $8.90 |
| Indicator | BRSP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 31.44 |
| Support Level | $5.49 | $4.78 |
| Resistance Level | $6.00 | $7.02 |
| Average True Range (ATR) | 0.14 | 0.41 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 32.08 | 11.45 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.